The aim is to find and treat lung cancers early, before they grow and spread, to improve the chance of survival. Here’s what’s involved.

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

Of course being diagnosed with metastatic non-small cell lung cancer (NSCLC) feels overwhelming. Between juggling treatments, managing symptoms and side effects, and dealing with the anxiety of a ...

The GINA 2025 asthma update includes new guidance on T2 biomarkers, asthma in young children, and climate change, as well as ...

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...